BSAC先锋系列:抗微生物药物耐药性宣传的未来
本文为BSAC先锋系列评论,探讨抗微生物药物耐药性(AMR)宣传的未来。作者指出COVID公共卫生紧急事件凸显全球相互关联性,AMR作为「缓慢移动」的威胁难以识别和应对,但仍有时间改变方向;科学家和卫生专业人员的宣传是强大工具,但存在陷阱,须明智使用,作者提出若干实现方式。
要点
- COVID公共卫生紧急事件凸显人类对不可控力量的脆弱性及全球健康相互关联。
- AMR是「缓慢移动」的威胁,使其更难被识别和应对。
- 科学家和卫生专业人员的宣传是改变AMR进程的强大工具,但存在陷阱,须明智使用。
核心结论
- 尽管对未来AMR影响的预测严峻,我们仍有时间改变方向;科学家和卫生专业人员的宣传是这一过程中的强大工具,但存在陷阱,必须明智使用,作者提出若干实现方式。
研究设计与样本
- 本文为BSAC先锋系列评论文章,未报告系统检索范围或样本量。
主要发现
- COVID公共卫生紧急事件凸显人类对不可控力量的脆弱性;AMR是「缓慢移动」的威胁,更难识别和应对;难以将地球上每个人的行动与健康视为相互关联曾使情况更糟,COVID大流行改变了这一点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID public health emergency has brought home how vulnerable we are to forces beyond our control. We are losing our ability to treat infectious diseases for a number of reasons, including antimicrobial resistance (AMR). AMR is a 'slow-moving' threat, which makes it harder to recognize and address. The situation has not been helped by the difficulty we have had in seeing the actions and health of everyone on this planet as interconnected. The COVID pandemic has changed this. Despite the dire predictions of the effect of AMR in the future, we still have time to change course. Advocacy by scientists and health professionals is a powerful tool in this process, but there are pitfalls and it must be used wisely. In this article I suggest a number of ways in which this can be achieved.
引用
- Osterholm MT. BSAC Vanguard Series: the future of ADVOCACY on AMR. J Antimicrob Chemother. 2021. PMID: 34792141. doi:10.1093/jac/dkab410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。